The Companion Diagnostics Market Will Be Worth Over $10bn In 2020 Predicts New Visiongain Report

10 September 2018
Pharma

A new report by visiongain predicts that the Companion Diagnostics market will exceed $10bn by 2020. This forecast and others appear in The Companion Diagnostics (CDx) Market Forecast 2016-2026: Leading Companies, Trends and Developments in the Growing Theranostics Market, published in March 2016. Visiongain is a business information provider based in London, UK.

The report examines the current and future trends in the Companion Diagnostics market. Companion Diagnostics are tests designed to confirm the presence of a specific biomarker and assist clinicians in selecting effective therapies for their patients. By the FDA definition, a companion diagnostic device “can be an in vitro diagnostic device or an imaging tool that provides information that is essential for the safe and effective use of a corresponding therapeutic product.” We are now at a point where an increasing number of targeted therapeutic products have reached the market and there are a great number of therapies currently in late-stage clinical trials that have the potential to enter into the market in the next 10 years. These products require the use of an associated diagnostic test in order to stratify patient populations and prescribe the medicine to the group of patients that will benefit the most from the product. The companion diagnostics market is set to show very strong growth as the cost saving potential of these tests becomes more apparent over the forecast period. Given the very high prices of a growing number of therapies, companion diagnostics can deliver savings to healthcare systems using this as a tool to reduce drug wastage. This makes understanding the companion diagnostics market and the opportunities available crucial for all those in fields related to the sector.

In this report, we examine the sales and provide forecasts to 2026 for a wide range of diagnostics products in the following submarkets: Theranostics and Other Companion Diagnostics. Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market. An analysis of existing partnerships, upcoming pipeline candidates with associated CDx programs and business strategies used by the companies involved in the sector are also included for all of the major submarkets. The prospects for the twelve leading national markets in the companion diagnostics market, including the US, Germany, France, Italy, Spain, the UK, Japan, China, India, Russia, Brazil and South Korea and Asia-Pacific are also included in this report. Using both primary and secondary research, forecasts have been built for the major submarkets and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the Companion Diagnostics market. Historical financial performance over 5 years is analysed, along with a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: “As targeted therapies become increasingly common, companion diagnostics, which allow for precise segmentation of patient populations will become vital in ensuring that the correct medicine is prescribed for each individual patient. Although they are mostly used in oncology at present, companion diagnostics have the potential to expand into other disease areas over the forecast period. Further advancements in technology will permit pharmaceutical companies to begin offering targeted therapies for more indications. This expansion, coupled with the potential for healthcare cost savings by reducing drug wastage through the use of companion diagnostics to enhance patient selection, will help to drive growth in the companion diagnostics market over the next ten years.”
Visiongain’s report provides revenue forecasts to 2026 for the companion diagnostics market and its leading submarkets and international markets. The report discusses selected leading companies which hold significant shares of the market. These companies include F. Hoffmann-La Roche Ltd, Qiagen N.V., Abbott Laboratories, Agilent Technologies, Myriad Genetics bioMerieux and Thermo Fisher Scientific. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

The Companion Diagnostics (CDx) Market Forecast 2016-2026: Leading Companies, Trends and Developments in the Growing Theranostics Market adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1